TNFSF11 and neoplasm: Specifically, for patients with pretreatment BMD < BMDA, clinicians should conduct a comprehensive assessment incorporating other clinical indicators (such as tumor stage, albumin levels) to optimize the treatment plan, and consider the use of immunomodulators and bone‐protective agents (e.g., anti‐RANKL drugs) to improve bone metabolism and hopefully enhance the response to immunotherapy.